Cargando…

Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer

BACKGROUND: Both apatinib and programmed death 1 (PD-1) monoclonal antibody (mAb) monotherapy have been licensed in China for the third-line treatment of advanced gastric cancer (AGC). However, whether the combination could improve the prognosis of patients with AGC after second-line treatment has n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, Qingli, Mao, Yuefeng, Wu, Daoyuan, Hu, Yanhui, Ma, Dongyang, Zhang, LiHan, Liu, Huaimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650409/ https://www.ncbi.nlm.nih.gov/pubmed/36387189 http://dx.doi.org/10.3389/fonc.2022.952494

Ejemplares similares

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer
por: Han, Guohu, et al.
Publicado: (2023)

A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
por: Cui, Qingli, et al.
Publicado: (2021)

Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study
por: Lin, Haimin, et al.
Publicado: (2019)

Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients
por: Pan, Dengdeng, et al.
Publicado: (2022)

The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer
por: Zhai, Chongya, et al.
Publicado: (2021)

Expression of p53 as a biomarker in determining response to apatinib for advanced gastric cancer
por: Qiu, Zhiyuan, et al.
Publicado: (2023)

Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
por: Qu, Jinglei, et al.
Publicado: (2023)

Careful dose modification of apatinib as third or further-line treatment in advanced gastric cancer patients with poor performance status
por: Chen, Jianxin, et al.
Publicado: (2019)

The full management from first-line to third-line treatments in patients with Her-2–negative advanced gastric cancer
por: Chang, Chunxiao, et al.
Publicado: (2022)

Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma
por: Wang, Yonggang, et al.
Publicado: (2022)

Nanodrugs systems for therapy and diagnosis of esophageal cancer
por: Zhang, Lihan, et al.
Publicado: (2023)

Apatinib combined with S-1 as second-line therapy in advanced gastric cancer
por: Qiu, Zhi-Yuan, et al.
Publicado: (2021)

Efficacy and safety of third-line or later-line targeted treatment for patients with metastatic colorectal cancer: a meta-analysis
por: Xue, Wen-Hui, et al.
Publicado: (2023)

Anti-Tumor Effect of Apatinib and Relevant Mechanisms in Liposarcoma
por: Cui, Lixuan, et al.
Publicado: (2021)

Role of Systemic Treatment for Advanced/Metastatic Gastric Carcinoma in the Third-Line Setting: A Bayesian Network Analysis
por: Pan, Wen-Tao, et al.
Publicado: (2020)

Comparison of the efficacy and safety of third-line treatments for advanced gastric cancer: A systematic review and network meta-analysis
por: Zhang, Chan, et al.
Publicado: (2023)

Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer
por: Zhai, Xiaoyang, et al.
Publicado: (2020)

Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor
por: Cai, Zhaolun, et al.
Publicado: (2019)

Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study
por: Xia, Wei-Li, et al.
Publicado: (2022)

Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR
por: Fang, Shencun, et al.
Publicado: (2017)

Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study
por: Liang, Jianmiao, et al.
Publicado: (2020)

Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis
por: Huang, Miao, et al.
Publicado: (2021)

Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2022)

Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study
por: Wu, Kunpeng, et al.
Publicado: (2023)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
por: Gong, Taojun, et al.
Publicado: (2022)

A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma
por: Yang, Qing, et al.
Publicado: (2023)

PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study
por: Wei, Qing, et al.
Publicado: (2020)

Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma
por: Li, Xiaofen, et al.
Publicado: (2018)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021)

Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kan, Xuefeng, et al.
Publicado: (2020)

Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study
por: Wang, Chunjing, et al.
Publicado: (2023)

Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
por: Zhang, Le, et al.
Publicado: (2023)

Case Report: Durable Clinical Response to Third-Line Pyrotinib After Resistance to Trastuzumab in a Gastric Cancer Patient
por: Wu, Junyi, et al.
Publicado: (2022)

The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study
por: Wang, Dongxu, et al.
Publicado: (2021)

The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
por: Wang, Jianzheng, et al.
Publicado: (2022)

The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies
por: Wang, Xuan, et al.
Publicado: (2020)

Apatinib as a Third-Line Treatment for HER2-Positive Metastatic Gastric Cancer: A Multi-Center Single-Arm Cohort Study
por: Zhang, Xin, et al.
Publicado: (2022)

Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma
por: Yang, Yonghao, et al.
Publicado: (2021)

Efficacy and safety of apatinib monotherapy for patients with advanced breast cancer: a systematic review and meta-analysis
por: Huang, Xuchen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tgitnjep6kfn9n5hinhdqqjgt0